Insider · CIK 0001761366
Sarah Kathryn Rouan
Files at VKTX (Viking Therapeutics, Inc.). First filing Oct 25, 2024, latest Apr 8, 2025.
Sarah Kathryn Rouan files SEC Form 4 as director at VKTX (Viking Therapeutics, Inc.). Since Oct 25, 2024, Sarah Kathryn Rouan has reported 2 open-market buys worth $60k and 1 open-market sell worth $890k, the latest filed on Apr 8, 2025.
A track record needs three past buys with six months of prices behind them; Sarah Kathryn Rouan has 0, so none is measured yet.
The newest scored trade: bought $30k of VKTX on Mar 31, 2025, filed Apr 8, 2025, scored 46 (moderate).
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
VKTX: Viking Therapeutics, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 46Moderate | VKTXbuy Viking Therapeutics, Inc. | $30k 1,240 shares | - | 0% from low-69% from high | |
| 46Moderate | VKTXbuy Viking Therapeutics, Inc. | $30k 1,240 shares | - | 0% from low-69% from high | |
| 38Weak | Viking Therapeutics, Inc. | $890k 11,000 shares | -100% | - |
Planned sales
Form 144 notices this insider filed before selling restricted or control stock, newest first.
| Filed | Company | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Oct 25, 2024 | VKTX Viking Therapeutics Inc | 11,000 0.01% of outstanding | $889k | Oct 25, 2024 | none |
Transactions
Every row this insider has filed, 7 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jan 2, 2026 | VKTX Viking Therapeutics, Inc. | AGrant or award Common Stock, par value $0.00001 per share | +3,150 | $0.00 | $0 | 4,390 | Jan 5, 2026 |
| Jan 2, 2026 | VKTX Viking Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +20,400 | $0.00 | $0 | 20,400 | Jan 5, 2026 |
| Mar 31, 2025 | VKTX Viking Therapeutics, Inc. | POpen-market purchase Common Stock, par value $0.00001 per share | +1,240 | $24.15 | $30k | 1,240 | Apr 8, 2025 |
| Mar 31, 2025 | VKTX Viking Therapeutics, Inc. | POpen-market purchase Common Stock, par value $0.00001 per share | +1,240 | $24.15 | $30k | 1,240 | Apr 2, 2025 |
| Oct 25, 2024 | VKTX Viking Therapeutics, Inc. | MOption exercise Common Stock, par value $0.00001 per share10b5-1 | +11,000 | $4.88 | $54k | 11,000 | Oct 25, 2024 |
| Oct 25, 2024 | VKTX Viking Therapeutics, Inc. | SOpen-market sale Common Stock, par value $0.00001 per share10b5-1 | -11,000 | $80.89 | $890k | 0 | Oct 25, 2024 |
| Oct 25, 2024 | VKTX Viking Therapeutics, Inc. | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -11,000 | $0.00 | $0 | 11,000 | Oct 25, 2024 |
Questions about Sarah Kathryn Rouan
Answered from the filings on this page, as of the latest one.
Is Sarah Kathryn Rouan buying or selling?
Not in the last 12 months. Sarah Kathryn Rouan's latest open-market trade on SEC Form 4 was bought $30k of VKTX on Mar 31, 2025.
How did Sarah Kathryn Rouan's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Sarah Kathryn Rouan has 0.
Where does Sarah Kathryn Rouan file Form 4?
Sarah Kathryn Rouan has filed Form 4 at VKTX (Viking Therapeutics, Inc.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.